What is Immunophotonics?
Immunophotonics, Inc. is a privately owned clinical-stage biotech company pioneering the field of Interventional Immuno-Oncology™. IP-001, the first asset from the company’s intellectual property platform, has the potential to overcome the local defenses of the tumor microenvironment to enable a tumor-specific anticancer immune response in multiple solid tumor indications. The company is in phase 2 development and is based in St. Louis, Missouri, USA with subsidiaries in Bern, Switzerland and Tianjin, China.
Be a Part of the Movement
We champion extraordinary entrepreneurs to create positive change – for St. Louis and for the world. Join us by applying to our Global Startup Competition, becoming a financial supporter, volunteering your time or amplifying our message.